Table 3.
Patient’s characteristics and outcomes: overall survival, disease-free survival and local-recurrence free survival
| Measurement | Number of patients | 3-year overall survival (%) | P value* | 3-year disease free survival (%) | P value* | 3-year local relapse free survival (%) | P-value* | |
|---|---|---|---|---|---|---|---|---|
| Treatment |
Standard |
139 |
62.9 |
0.742 |
59.8 |
0.496 |
60.5 |
0.647 |
| Brachytherapy |
134 |
63.3 |
52.6 |
54.4 |
||||
| Country |
A |
118 |
59.8 |
0.222 |
49.9 |
0.124 |
51.7 |
0.283 |
| B |
29 |
45.2 |
37.2 |
40.9 |
||||
| C |
76 |
71.3 |
67.1 |
67.1 |
||||
| D |
25 |
70.1 |
60.0 |
60.0 |
||||
| E |
25 |
68.8 |
68.7 |
68.7 |
||||
| Age (years) |
<40 yrs |
105 |
71.5 |
0.014 |
64.4 |
0.125 |
66.8 |
0.058 |
| ≥40 yrs |
168 |
57.6 |
50.6 |
51.1 |
||||
| Sex |
Male |
197 |
63.3 |
0.540 |
56.2 |
0.442 |
57.6 |
0.394 |
| Female |
76 |
61.5 |
55.8 |
56.6 |
||||
| WHO pathology |
1-2 |
65 |
61.4 |
0.949 |
53.9 |
0.461 |
54.8 |
0.438 |
| 3 |
208 |
63.6 |
56.7 |
58.0 |
||||
| Stage |
T3-4 & N2-3 |
70 |
50.6 |
0.024 |
45.3 |
0.018 |
46.2 |
0.016 |
| Others |
203 |
66.5 |
59.3 |
60.6 |
||||
| Chemotherapy |
No |
35 |
75.2 |
0.159 |
65.4 |
0.136 |
65.4 |
0.184 |
| Yes |
238 |
60.4 |
54.7 |
56.2 |
||||
| T Stage |
T1&T2 |
140 |
|
|
|
|
59.0 |
0.372 |
| T3&T4 |
133 |
|
|
|
|
55.3 |
||
| T Stage & N | T1/T2N+ |
129 |
|
|
|
|
54.9 |
0.683 |
| Others | 144 | 59.8 |
*P-value ≤ 0.05 is considered significant. WHO = World Health Organization. N = Lymph node status.